Abbott Wins FDA Clearance For CardioMEMS App Upgrade, Adding At-Home Pressure Visibility
The Catalyst Brief
Coverage
Medical Technology
Digital health, diagnostics and medical devices, and the signals that matter for adoption, reimbursement and outcomes.
Latest
Abbott Launches SimpleScreen CRC In The U.S., Adding A Blood-Based Option For Unscreened Average-Risk Adults
The Catalyst Brief
DreaMed Wins FDA Clearance For MODI, Expanding Insulin Automation To More Complex Type 2 Regimens
The Catalyst Brief
Cordis Wins FDA Approval For Selution SLR DEB, Opening A U.S. Sirolimus Balloon Option In Coronary ISR
The Catalyst Brief
Most read
STAT Investigation Examines Commure’s Referral Payments And Customer Losses, As AI Health-Care Sales Scale
The Catalyst Brief
What OpenAI and Anthropic’s Healthcare Push Means for the Industry
The Catalyst Brief
Whole-Body MRI Companies Face Scrutiny Over Inflated Medical Claims
The Catalyst Brief
What AI Is Getting Right—and Wrong—in Healthcare Revenue Cycle Management
The Catalyst Brief
More in this beat
Sep 19, 2026Medtronic Wins FDA Clearance For LigaSure RAS Maryland Jaw With Hugo, Expanding U.S. Robotic Surgery Workflow
The clearance lets Medtronic pair the Hugo robotic-assisted surgery system in the U.S. with a LigaSure instrument already established in open and laparoscopic surgery. Strategically, the move is less about novelty than about making Hugo more usable in real operating-room workflows as competition in robotic surgery increases.
The Catalyst Brief
Sep 13, 2026Powerful Medical Wins De Novo EKG Classification, Opening A Higher-Evidence AI Triage Route
Powerful Medical’s model is aimed at a harder, time-sensitive use case: helping direct chest-pain patients to the right care when a coronary artery is completely blocked. In a market crowded with AI tools for screening and prevention, the de novo decision signals that acute-care algorithms may need stronger evidence and clearer regulatory differentiation.
The Catalyst Brief
Sep 13, 2026GE HealthCare Eyes Up To $1 Billion Sofie Biosciences Deal, Expanding Imaging Chemicals Reach
The Financial Times reported, citing people familiar with the matter, that GE HealthCare could announce a Sofie Biosciences acquisition as soon as this coming week. Neither company has commented on the report. Strategically, the move would strengthen GE’s pharma diagnostics business as the company reshapes its imaging operations and reviews other units.
The Catalyst Brief
Sep 2, 2026Medtronic Recalls Bravo CF Capsule Delivery Devices After 184 Serious Injuries, Reviving A Prior Failure Mode
The FDA issued an early alert after Medtronic sent customers an August 6 letter about the problem. The event matters commercially because it affects a wireless reflux-monitoring device already tied to a June 2025 recall, even though the company said the underlying cause is different this time.
The Catalyst Brief
Sep 1, 2026Boston Scientific Halts Imager II Catheter Sales After Two Serious Injuries, Adding To A Difficult Year
The issue centers on reduced levels of stabilizing agents in catheter tips, which could increase the risk of degradation and detachment. For Boston Scientific, the halt adds a device safety problem to a year already marked by a cyberattack, restructuring and lower top-end guidance.
The Catalyst Brief
Aug 25, 2026Implantica Wins FDA Approval For RefluxStop, Eight Years After European Launch
RefluxStop is designed to reduce or stop acid from entering the oesophagus through an implant placed on the upper part of the stomach via keyhole surgery. The approval brings the device into the U.S. after years on the European market, but Implantica is signaling a gradual commercial rollout centered on selected centers and physician training.
The Catalyst Brief
Aug 24, 2026Roche And Eli Lilly Win FDA Clearance For Elecsys pTau217, Opening A New Alzheimer’s Blood-Test Step
The assay detects phosphorylated Tau 217 protein, which has been linked to amyloid plaque buildup in the brain. Commercially, the clearance points to a broader diagnostic pathway that could move Alzheimer’s assessment beyond PET imaging and cerebrospinal fluid testing in selected patients.
The Catalyst Brief
Aug 23, 2026STAT Details Focal Therapy’s Rise In Prostate Cancer As Guidelines Still Limit Use
New long-term U.K. data gave focal therapy supporters fresh evidence, including a reported 0.1% prostate cancer mortality rate 10 years after treatment. Even so, debate persists because randomized comparisons with standard treatment remain limited and real-world use extends beyond the patients guidelines say should receive it.
The Catalyst Brief
Aug 21, 2026Focal Therapy Posts 0.1% Prostate Cancer Mortality At 10 Years, While U.S. Guidelines Still Call It Experimental
Focal therapy aims to destroy MRI-visible prostate lesions without removing or irradiating the whole gland, offering a less aggressive option than surgery or radiation for some patients with localized disease. A recent 10-year U.K. study reported 0.1% prostate cancer mortality, but the American Urological Association still says the approach should be limited to studies and prospective registries.
The Catalyst Brief
Aug 12, 2026STAT Investigation Examines Commure’s Referral Payments And Customer Losses, As AI Health-Care Sales Scale
Commure, a Mountain View technology company valued at $7 billion, is pitching AI tools meant to automate billing, scheduling, and clinical documentation across health care. The STAT report puts the focus less on product ambition than on the commercial methods and customer outcomes shaping adoption as AI moves deeper into provider operations.
The Catalyst Brief
Aug 8, 2026Healthcare Workplace Violence Prevention: Why Risk Visibility Must Improve
Although healthcare organizations routinely collect data on potential risk indicators, the inability to connect disparate pieces of information often leads to missed warning signs and reactive, rather than proactive, prevention efforts. This extended analysis explores the systemic barriers and examines pathways toward more effective workplace violence prevention in healthcare—including the critical role of emerging data technologies.
The Catalyst Brief
Aug 7, 2026Rethinking Preventive Dental Care: Why the Bite Is the Missing Piece
While dentistry’s preventive paradigm has long targeted cavities and periodontal disease, new thought leadership emphasizes that how teeth, muscles, and the jaw interact over a lifetime plays a foundational role in holistic oral health. As emerging science connects bite function to chronic dental problems, the industry is re-examining what truly constitutes prevention.
The Catalyst Brief
Other beats
AI in Drug Discovery
Machine learning, predictive models and computational biology: how AI is changing discovery workflows and probability of success.
Biopharmaceutical Industry
Drug development, clinical trials and industry dynamics. What changes timelines, risk and competitive positioning.
Biotech Innovation
Gene therapy, CRISPR, synthetic biology and emerging platforms. Separating what is real from what is hype, and what actually translates.
Healthcare Investment
Where capital is flowing and why the tape moves, across funding rounds, M&A, IPOs and market analysis.
Regulatory & Policy
FDA actions, approvals, policy shifts and compliance: how the rules change timelines and probability.